IPO Plus

₹14.31

▼ -0.7 -4.66%

As of 26 Oct 2026 · delayed

BSE Listed

GSM · GSM 0
What does GSM · GSM 0 mean?
BSE · Graded Surveillance Measure (GSM 0)GSM targets fundamentally weak companies whose price doesn't square with their financials (tiny net worth or negative/extreme P/E). Practical meaning: the exchange doubts the price is backed by the business. Stage 0 is a watchlist; each higher stage makes the stock progressively harder to trade — tighter bands, full upfront margin, weekly-only trading, and at Stage IV no upward price movement at all. Exiting requires a quarterly review finding the criteria no longer met.Criteria: Shortlisted on objective financial parameters — net worth, net fixed assets, price-to-earnings multiple and market capitalisation. Stage 0 = base surveillance watchlist (identified under GSM, no graded price restriction yet); Stages I–VI add escalating curbs (price band, 100% margin, periodic call auction, settlement on a gross/trade-for-trade basis, no upward price movement).

Norris Medicines Ltd. (524414)

Volume: 429Avg Vol 1W: 776Avg Vol 1M: 96852W Range:₹12₹20.06
BSE www.norrispharma.com AI Report
Key Ratios
Checked 9h ago
Market Cap₹14 Cr
Current Price₹14.31
Previous Close₹15.01
High / Low (52w)₹20.06 / ₹12
Volume429
Avg Vol (1W)776
Avg Vol (1M)968
Stock P/E—
Book Value₹-15.07
Dividend Yield0%
ROE185.24%
ROA-287.04%
Revenue (TTM)—
Revenue Growth—
Profit Margin-486.84%
Total Debt—
Shares Outstanding1 Cr
Face Value—
EPS (TTM)₹0
P/B—
Debt / Equity0
50 DMA₹16.05
200 DMA₹14.79
Day change-4.66%
SurveillanceGSM · GSM 0
Price Chart
₹14.31▼ 9.20% · 1Y
₹20₹1210K
2025-10-27
2026-10-26

20-day avg volume: 706 shares

Pros
  • Healthy return on equity of 185.2%.
  • Company is almost debt-free.
  • Revenue grew 39% YoY.
Cons
  • Company is loss-making at the latest annual result.
  • Negative book value per share.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹1 Cr₹1 Cr₹3 Cr₹1 Cr₹2 Cr₹3 Cr₹1 Cr₹1 Cr
EBITDA₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹-1 Cr₹1 Cr₹0 Cr₹0 Cr
Net Profit₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹-1 Cr₹1 Cr₹0 Cr₹0 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue₹16 Cr₹8 Cr₹12 Cr₹9 Cr₹8 Cr₹6 Cr₹6 Cr₹8 Cr
EBITDA₹-1 Cr₹-3 Cr₹-2 Cr₹-1 Cr₹0 Cr₹-1 Cr₹-1 Cr₹0 Cr
Net Profit₹-2 Cr₹-3 Cr₹-5 Cr₹-3 Cr₹-2 Cr₹-1 Cr₹-1 Cr₹0 Cr
EPS-1.68-2.84-4.96-3.26-1.75-1.19-1.24-0.28
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹20 Cr₹21 Cr₹20 Cr₹14 Cr₹14 Cr₹14 Cr₹14 Cr₹13 Cr
Total Liabilities₹20 Cr₹23 Cr₹27 Cr₹25 Cr₹26 Cr₹28 Cr₹29 Cr₹28 Cr
Equity₹0 Cr₹-2 Cr₹-7 Cr₹-11 Cr₹-12 Cr₹-14 Cr₹-15 Cr₹-15 Cr
Total Debt————————
Cash Flow
MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹1 Cr₹-1 Cr₹1 Cr₹0 Cr₹1 Cr₹1 Cr
Investing₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Financing₹-1 Cr₹1 Cr₹-1 Cr₹0 Cr₹-1 Cr₹-1 Cr
Free Cash Flow₹1 Cr₹-1 Cr₹1 Cr₹0 Cr₹1 Cr₹1 Cr
Shareholding
Promoter 34.01% Institutions 0.07% Public 65.92%
Efficiency & Working Capital
ROCE3.4%
Interest Coverage0.4
Dividend Payout—
Debtor Days53 d
Inventory Days179 d
Payable Days118 d
Cash Conversion Cycle114 d
Working Capital Days232 d
Shareholding Details

As of 2026-09-30

Promoter34%
FII0%
DII0.1%
Institutions0.1%
Public65.9%
Promoter Pledge0%
No. of Shareholders25,628
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodDec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026Sept 2026
Promoters34%34%34%34%34%34%34%34%34%34%34%34%
FIIs0%0%0%0%0%0%0%0%0%0%0%0%
DIIs0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%0.1%
Public65.9%65.9%65.9%65.9%65.9%65.9%65.9%65.9%65.9%65.9%65.9%65.9%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders25,31725,51725,40025,49825,65925,81525,95025,89525,79125,77725,77725,628
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Fab Metals Private LimitedPublic Shareholding42%41,99,259
Vimal D ShahShareholding of Promoter and Promoter Group23.6%23,60,441
Navsarjan Investment & Trading Pvt LtdShareholding of Promoter and Promoter Group10%10,00,000
Lkp Securities LimitedPublic Shareholding1.5%1,50,000
Dhirendra Kantilal Shah HufShareholding of Promoter and Promoter Group0.3%34,350
Navnit Jethabhai PatelShareholding of Promoter and Promoter Group0%3,840
Milind L UpadhyayaShareholding of Promoter and Promoter Group0%1,500
Nimish Bhishma ThakoreShareholding of Promoter and Promoter Group0%1,440
Board of Directors
NameDesignationYear
Vimal D ShahChairman / Executive Director / Managing Director2025
Angamuthu VadivelIndependent Non Exe. Director2025
Praveen BafnaNon-Exec & Non-Independent Dir2025
Sathya VenkatachalamIndependent Non Exe. Director2025
Priyanka LohiaCompany Sec. & Compli. Officer2025
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹10101010
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-14Board Meetings—
Company Information
Incorporated1990
ChairmanVimal D Shah
AuditorBahedia & Associates
Investor Email[email protected]; [email protected]
🌐 www.norrispharma.com ↗

📍 Plot No 801/P & 802, GIDC Industrial Estate, Ankleshwar, Gujarat, 393002

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Vimta LabsBiofil ChemicalsIshita Drugs & Industries Ltd.Marksans PharmaUniversal Starch Chem Allied Ltd.Aarey Drugs & PharmaceuticalsAsian Petroproducts & Exports Ltd.Camex Ltd.Evexia Lifecare LimitedIndo Euro Indchem Ltd.Syncom FormulationsRiddhi Siddhi Gluco Biols Ltd.All “52” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search

Telegram App